M
Margaret A. Fischl
Researcher at University of Washington
Publications - 20
Citations - 4289
Margaret A. Fischl is an academic researcher from University of Washington. The author has contributed to research in topics: Zidovudine & Asymptomatic. The author has an hindex of 15, co-authored 20 publications receiving 4245 citations. Previous affiliations of Margaret A. Fischl include University of California, San Diego & Stanford University.
Papers
More filters
Journal ArticleDOI
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial.
Margaret A. Fischl,Douglas D. Richman,M. H. Grieco,M. S. Gottlieb,Paul A. Volberding,Oscar L. Laskin,John M. Leedom,Jerome E. Groopman,Donna Mildvan,Robert T. Schooley +9 more
TL;DR: It is demonstrated that AZT administration can decrease mortality and the frequency of opportunistic infections in a selected group of subjects with AIDS or AIDS-related complex, at least over the 8 to 24 weeks of observation in this study.
Journal ArticleDOI
Circulating p24 Antigen Levels and Responses to Dideoxycytidine in Human Immunodeficiency Virus (HIV) Infections: A Phase I and II Study
Thomas C. Merigan,Gail Skowron,Samuel A. Bozzette,D. D. Richman,Raj Uttamchandani,Margaret A. Fischl,Robert T. Schooley,Martin S. Hirsch,Whaijen Soo,Carla P. Pettinelli,Herbert Schaumburg +10 more
TL;DR: Less toxic regimens of dideoxycytidine merit clinical assessment for advanced anti-human immunodeficiency virus-1 (HIV) infection in patients with AIDS or advanced AIDS-related complex.
Journal ArticleDOI
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
Tze-Chiang Meng,Margaret A. Fischl,Ahmad M. Boota,Stephen A. Spector,Donald Bennett,Yiannis Bassiakos,Shenghan Lai,Brian Wright,Douglas D. Richman +8 more
TL;DR: Combination therapy with ddC and higher doses of zidovudine produced greater and more persistent effects in patients with advanced HIV infection compared with other study regimens and with the results of previous trials.
Journal ArticleDOI
Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy.
Richard W. Price,Constantin T. Yiannoutsos,David B. Clifford,Lawrence Zaborski,Alex Tselis,John J. Sidtis,Bruce A. Cohen,Colin D. Hall,Alejo Erice,Keith Henry,M. Glicksman,William G. Powderly,Susan Swindells,G. Rudberg,Curtis Cooper,Harold A. Kessler,Michael J. Borucki,P. Galatas,C. Van Der Horst,C. Kapoor,Kevin Robertson,Wendy T. Robertson,David M. Simpson,D. Dorfman,B. Sinclair,C. Olson,Karen Marder,M. Crawford,T. Flynn,Christine Wanke,Donald E. Craven,J. Reid,Robert G. Holloway,Kenneth H. Fife,K. Todd,Camillo Marra,Ann C. Collier,Dana Cummings,Kenneth L. Tyler,Beverly Putnam,Harry Hollander,J. Walker,I. Matozzo,Ian Frank,Princy Kumar,Mario Guerrero,S. Kruger,Margaret A. Fischl,E. Scerpella,Allan Rodriguez,Peter T. Frame,S. Kohrs,Michael M. Lederman,Guillermo J. Vázquez,I. Lopez,Robert Delapenha,Y. Butler,Michael S. Saag,Kathleen Squires,S. Deloach,B. McCulloch,E. Cooney,C. Frank,M. J. Nealon,Laura Ponticello,R. Sociro,Fred T. Valentine,Mary A. Vogler,Keith Chirgwin,S. Szebenyi,M. Rinki,Debbie Slamowitz,D. Ogata-Arakaki,Monica Millard,Ronald J. Ellis,R. Snyder,M. E. Eyster,C. Ehmann,C. Kessler,C. Quinlan,D. B. Brettler,P. Forand,S. Seremetis,M. Brady,J. Hunkler,H. Saba,B. Tannenbaum,K. Hoots,T. D. Coates,A. Sosa,M. A. South,A. Rubinstein,J. Weiler-Einstein,John Gill,P. Timmons,Stacy M. Stabler,S. Giambartolomei,P. Clax,A. Kenton +98 more
TL;DR: The significant association of poor neurological performance with mortality, independent of CD4 counts and HIV-1 RNA levels indicates that neurological dysfunction is an important cause or a strong marker of poor prognosis in late HIV- 1 infection.
Journal ArticleDOI
The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.
Paul A. Volberding,Stephen W. Lagakos,Janet M. Grimes,Daniel S. Stein,Henry H. Balfour,Richard C. Reichman,John Bartlett,Martin S. Hirsch,John P. Phair,Ronald T. Mitsuyasu,Margaret A. Fischl,Ruy Soeiro +11 more
TL;DR: Zidovudine at 500 mg/d caused a significant delay in progression to AIDS or death, but its earlier use in asymptomatic disease was not associated with an additional prolongation of survival compared with delayed initiation.